ライフサイエンスコーパス: hematological disorder

1 g the importance of PTN in the growth of any hematological disorder.

2 Polycythemia vera (PV) is a human clonal hematological disorder.

3 development of expansion strategies to treat hematological disorders.

4 ting, focusing on its potential for treating hematological disorders.

5 targeting the treatment of immunological and hematological disorders.

6 iously received a bone marrow transplant for hematological disorders.

7 ion (BMT) represents a cure for nonmalignant hematological disorders.

8 ant clinical traits and can indicate various hematological disorders.

9 could be extrapolated to MSC dysfunction in hematological disorders.

10 ation, variable chromosomal instability, and hematological disorders.

11 acute myeloid leukemia and treatment-related hematological disorders.

12 zebrafish as a genetic model to study human hematological disorders.

13 hroughput genetic screening for these common hematological disorders.

14 s for the treatment of B19V infection-caused hematological disorders.

15 s for the treatment of B19V infection-caused hematological disorders.

16 or the diagnostic workup of a broad range of hematological disorders.

17 n for perioperative anemia and management of hematological disorders.

18 ilitate the development of new therapies for hematological disorders.

19 symptoms, frequently involving the skin and hematological disorders.

20 from the mild erythema infectiosum to severe hematological disorders.

21 single-step prenatal treatment of congenital hematological disorders.

22 represents a curative treatment for various hematological disorders.

23 owledge implicating the shelterin complex in hematological disorders.

24 There were 30 cancers, 9 malignant hematological disorders, 14 chronic inflammatory disease

25 Parvovirus B19 (B19V) infection can cause hematological disorders and fetal hydrops during pregnan

26 d progenitor cells (EPCs) and causes several hematological disorders and fetal hydrops.

27 outside the body is fundamental for managing hematological disorders and for the development of novel

28 Human parvovirus B19 (B19V) infection causes hematological disorders and is the leading cause of noni

29 Many hematological disorders and malignancies primarily resul

30 and increased incidence of anemia and other hematological disorders and malignancies.

31 data implicate hnRNP K in the development of hematological disorders and suggest hnRNP K acts as a tu

32 eme catabolism, is a key marker of liver and hematological disorders, and important cytoprotective pr

33 disease (aOR, 2.97; 95% CI, 1.65-5.37), or a hematological disorder (aOR, 3.10; 95% CI, 1.04-9.24) wa

34 effective antiviral of parvovirus B19 caused hematological disorders, as well as a carrier to deliver

35 with sickle cell disease (SCD), an inherited hematological disorder associated with vascular inflamma

36 DNA, and anti-histone autoantibodies, severe hematological disorders, autoimmune glomerulonephritis,

37 be used effectively for in silico studies of hematological disorders based on first principles and pa

38 went laparoscopic splenectomy for a range of hematological disorders between November 1992 and Februa

39 hotic drug bitopertin, might affect not only hematological disorders but multiorgan diseases such as

40 om of MDS, a rare group of potentially fatal hematological disorders, but it has not previously been

41 ntration, which are common manifestations of hematological disorders, can have hitherto unrecognized

42 Sickle cell disease (SCD) is a worldwide hematological disorder causing painful episodes, anemia,

43 cute myeloid leukemia (AML) is an aggressive hematological disorder comprising a hierarchy of quiesce

44 HCV infection," "HCV syndrome," "HCV-related hematological disorders," "extrahepatic manifestation,"

45 For many nonmalignant hematological disorders, HLA-matched bone marrow transpl

46 fungal infections in patients with high-risk hematological disorders; however, breakthrough infection

47 Human parvovirus B19 infection causes severe hematological disorders, including transient aplastic cr

48 ects hematopoietic stem cell (HSC) aging and hematological disorders is poorly understood.

49 Sickle cell disease (SCD) is a hematological disorder leading to blood vessel occlusion

50 regimen used in the context of nonmalignant hematological disorders leads to substantially higher ra

51 colitis (n=6), adrenal insufficiency (n=5), hematological disorders (n=3), dermatitis (n=1), and rhe

52 ts: IBD, n=67 (20.2%); RA, n=39 (11.8%); and hematological disorders, n=13 (3.9%).

53 quantitatively assess the impact of various hematological disorders on the retina using optical cohe

54 ree patients all had histories of underlying hematological disorders, presented with fever, and recov

55 nfections (bIFIs) in patients with high-risk hematological disorders receiving voriconazole or posaco

56 o O(2) transport and their relationship with hematological disorders remain ill defined.

57 Most nonmalignant hematological disorders require transfusion support prio

58 s used both in oncology and for treatment of hematological disorders such as sickle cell anemia where

59 Anemia is a hematological disorder that adversely affects the health

60 However, in many hematological disorders the spectrin network and lipid b

61 tem cells, describe progress toward modeling hematological disorders using iPS cells, and illustrate

62 rk toward the possible treatment of numerous hematological disorders using iPSC technologies.

63 Patients with various hematological disorders who underwent splenectomy betwee

64 ll prolymphocytic leukemia (B-PLL) is a rare hematological disorder whose underlying oncogenic mechan

65 Acute myelogenous leukemia is a hematological disorder with a predilection for gingival

66 Pure red cell aplasia (PRCA) is a rare hematological disorder with multiple etiologies.

67 anemia (SCA) is a well characterized severe hematological disorder with substantial morbidity and ea